Semaglutide cardiovascular outcomes in diabetes
study032
10.1056/NEJMoa1800869
New England Journal of Medicine
randomized clinical trial
Semaglutide evaluated for glycemic control and cardiovascular risk.
Improved glucose regulation and reduced cardiovascular risk markers.
semaglutide
metabolism|cardiometabolic
metabolic-stack
semaglutide-vs-tirzepatide
published